Related Experiment Video
Updated: Jun 27, 2025
15:17
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
14.0K
CD44: A New Prognostic Marker in Colorectal Cancer?
Pina Ziranu1, Andrea Pretta1, Valentina Aimola2
1Medical Oncology Unit, University Hospital and University of Cagliari, SS 554 km 4500 Bivio per Sestu, Monserrato, 09042 Cagliari, Italy.
Cancers
|April 27, 2024
Summary
Cluster of differentiation 44 (CD44), a cell surface glycoprotein, is overexpressed in cancer stem cells (CSCs), driving tumor progression. Understanding CD44 isoforms and their roles is crucial for developing targeted cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cluster of differentiation 44 (CD44) is a cell surface glycoprotein implicated in cancer stem cell (CSC) biology.
- Overexpression of CD44 in CSCs correlates with self-renewal, epithelial-mesenchymal transition (EMT), and resistance to cancer treatments.
- CD44 interacts with its ligand, hyaluronan (HA), activating signaling pathways that promote tumor cell proliferation, migration, and invasion.
Purpose of the Study:
- To review the diverse structures and functions of CD44 standard (CD44s) and variant (CD44v) isoforms in tumorigenesis.
- To explore the therapeutic implications of targeting CD44 and its isoforms in cancer treatment.
- To discuss emerging research on CD44's association with KRAS-dependent carcinomas, tumor mutational burden (TMB), and microsatellite instability (MSI).
Main Methods:
- Literature review of current research on CD44 structure, function, and therapeutic potential.
- Analysis of studies investigating CD44 expression in various cancer types and its correlation with clinical outcomes.
- Synthesis of information regarding CD44 signaling pathways and its interaction with hyaluronan.
Main Results:
- CD44, through its interaction with HA, plays a significant role in maintaining stemness and promoting tumor progression.
- Alternative splicing generates CD44s and CD44v isoforms with distinct functional roles that require further elucidation.
- CD44's involvement in KRAS-dependent cancers and its potential links to TMB and MSI highlight new therapeutic avenues.
Conclusions:
- CD44 and its isoforms are critical regulators of tumor progression and represent promising molecular targets for novel cancer therapies.
- Further research into the specific functions of CD44 isoforms is warranted to optimize therapeutic strategies.
- The association of CD44 with specific cancer subtypes and biomarkers like TMB and MSI offers opportunities for personalized cancer treatment.
